Page last updated: 2024-12-09

2-(1H-indol-3-yl)-2-oxo-N-(2-thiazolyl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 2-(1H-indol-3-yl)-2-oxo-N-(2-thiazolyl)acetamide: A Potential Drug Target

**2-(1H-indol-3-yl)-2-oxo-N-(2-thiazolyl)acetamide**, also known as **indomethacin**, is a **nonsteroidal anti-inflammatory drug (NSAID)**. It's a potent inhibitor of **cyclooxygenase (COX)** enzymes, primarily COX-1 and COX-2.

**Why is indomethacin important for research?**

* **Anti-inflammatory effects:** Indomethacin's ability to inhibit COX enzymes makes it effective in reducing inflammation. This is due to its ability to block the production of prostaglandins, which are chemicals that cause inflammation.
* **Pain relief:** Indomethacin is used to treat pain, particularly inflammatory pain associated with conditions like arthritis.
* **Fever reduction:** Indomethacin can also reduce fever by inhibiting the production of prostaglandins that stimulate the hypothalamus, the part of the brain that regulates body temperature.
* **Treatment of various conditions:** Indomethacin is used to treat a wide range of conditions, including:
* **Rheumatoid arthritis:** A chronic inflammatory disorder affecting the joints.
* **Osteoarthritis:** A degenerative joint disease causing cartilage breakdown.
* **Gout:** A condition caused by a buildup of uric acid in the body.
* **Migraines:** Severe headaches that can cause nausea and vomiting.
* **Menstrual cramps:** Painful cramps during menstruation.
* **Pericarditis:** Inflammation of the sac surrounding the heart.
* **Certain types of cancer:** Indomethacin shows potential in inhibiting cancer cell growth.

**Research Focus:**

* **Exploring new applications:** Researchers are exploring new uses for indomethacin, such as its potential in treating cancer and Alzheimer's disease.
* **Improving safety and efficacy:** Research aims to develop safer and more effective formulations of indomethacin, minimizing its potential side effects.
* **Understanding its mechanism of action:** Scientists continue to investigate how indomethacin interacts with various cells and tissues, particularly its interactions with different COX isoforms and other pathways.
* **Developing novel NSAIDs:** Research focuses on designing new NSAIDs with better efficacy and fewer side effects, potentially by targeting specific COX isoforms or exploring other therapeutic targets related to inflammation.

**Overall, indomethacin remains a crucial research subject due to its potent anti-inflammatory properties and its potential for treating various conditions. Research efforts continue to explore its full potential and address its limitations, paving the way for better treatment options in the future.**

Cross-References

ID SourceID
PubMed CID2174681
CHEMBL ID1517007
CHEBI ID122123
SCHEMBL ID11924959

Synonyms (19)

Synonym
STK710836
CCG-160196
smr000142417
MLS000534981
2-(1h-indol-3-yl)-2-oxo-n-1,3-thiazol-2-ylacetamide
CHEBI:122123
2-(1h-indol-3-yl)-2-oxo-n-(1,3-thiazol-2-yl)acetamide
AKOS001880873
SCHEMBL11924959
HMS2334J21
acetamide, 2-(1h-indol-3-yl)-2-oxo-n-thiazol-2-yl-
QXWUXNUOPOLUHR-UHFFFAOYSA-N
CHEMBL1517007
2-(1h-indol-3-yl)-2-oxo-n-(2-thiazolyl)acetamide
Q27210764
sr-01000251946
SR-01000251946-1
496028-70-7
2-(1h-indol-3-yl)-2-oxo-n~1~-(1,3-thiazol-2-yl)acetamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency7.56860.007215.758889.3584AID588342
ATAD5 protein, partialHomo sapiens (human)Potency5.93110.004110.890331.5287AID504466; AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency2.23870.28189.721235.4813AID2326
67.9K proteinVaccinia virusPotency12.58930.00018.4406100.0000AID720579
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.38720.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.54810.01262.451825.0177AID485313
importin subunit beta-1 isoform 1Homo sapiens (human)Potency100.00005.804836.130665.1308AID540263
ras-related protein Rab-9AHomo sapiens (human)Potency3.16230.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency100.00005.804836.130665.1308AID540263
survival motor neuron protein isoform dHomo sapiens (human)Potency11.22020.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency14.12540.00419.962528.1838AID2675
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]